HUTCHMED (China) Ltd
ORPATHYS
MET-amplified gastric cancer
Resolved
36days ago
Phase 2 readout · Jun 1, 2026
What's at stake
Phase 2 trial results for ORPATHYS in MET-amplified gastric cancer are due Jun 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 13h ago
“Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. Nat Med. Published online June 1, 2026.”